Colin Hill to Speak at The World Medical Innovation Forum 2022
This year, the World Medical Innovation Forum will explore the promise of new gene and cell therapies, the challenges to their development and investment and market dynamics. The forum features more than 200 CEOs, industry, investment, and government senior leaders from across the Gene and Cell Therapy (GCT) ecosystem. On Tuesday, May 3, Colin Hill, will […]
Meet us at AACR
The AACR Annual Meeting is the focal point of the cancer research community. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Meeting highlights the work of the best minds in cancer research from institutions all over the world. Joe F. Donahue, our Chief Business Officer […]
Colin Hill to Speak at The Longwood Healthcare Leaders Winter Webconference
On Thursday, January 6, Colin Hill, will be moderating a panel on Expediting Research for Treatments and Cures at the Longwood Healthcare Leaders winter webconference. He will be joined by Christopher Coburn, CIO, Mass General Brigham; Ray Deshaies, SVP, Research, Amgen; Raj Devraj, CEO, Rectify Pharma; Brian McVeigh, CEO, Code Biotherapeutics and Chen Schor, Chair, […]
WBUR Covers Convergence of AI and Precision Medicine
June 8, 2018 – WBUR, the largest of the three Boston NPR-affiliates, produced a series on the biotech boom in Boston this week, coinciding with the 2018 BIO conference that took place at the Boston Convention Center from June 4-7. Today, reporter Karen Weintraub dove into the rapidly converging fields of AI and precision medicine […]
Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms
CAMBRIDGE, Mass.– August 23, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company’s REFS™ causal machine learning and simulation platform and solutions […]